HEAL WELL. AGE WELL. LIVE LONGER.(800) 266-7207   ·   contact@clearhealthpass.com
Peptide science / Patient safety

Gray markets.
Patient safety first.

Putting medical necessity, qualified clinical judgment and patient safety ahead of a product promise.

What you don’t know can cause harm.

Know the substance.
Understand the evidence.
Consider the person.

Uncertain identity, quality or clinical context can introduce risk. Even an accurately identified substance may be inappropriate for a particular patient.

Clear Health Pass plans an approach built around assessment, consent, traceable supply and follow-up. It is a plan, not an available treatment or proof of benefit.

Explore the planned pathways↗
IDENTITYQUALITYNECESSITYFOLLOW-UP
PEOPLE
FIRST
Before the promise

Five questions worth asking.

Explore each question. This is an educational guide, not a test of treatment eligibility.

01 / Identity

What is actually in the product?

An online label or a research-use-only disclaimer does not establish the identity, suitability or lawful patient use of a substance. Know the exact product and its source.

Human judgment. Better information.

AI supports the record.
People guide the care.

Technology should help clinicians see a clearer picture, while keeping the patient’s needs and clinical judgment central.

CHP’s measurement, coverage documentation and audit tools support the clinical record; they do not independently establish that a peptide is safe, effective or medically necessary.

Meet the people behind the platform↗
“Research use only” is not a patient-use authorization. Legitimate prescribing, compounding and investigational pathways have distinct requirements. This page does not determine current substance eligibility, recommend treatment or provide dosing advice.

Source: FDA safety context ↗.

Make room for better questions.

Explore the education hub or speak with the team about the planned program.

Visit the Learning Hub↗